Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Case Report



Nilotinib induced skin rash in chronic myeloid leukemia patients: A case series

Nilesh Wasekar, Aniket B Mohite, Chandrakala S, Vinod P, Rajesh P, Shailesh B, Farah Jijina.

Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation of long arms of chromosomes 9 and 22 (Philadelphia chromosome). Since the approval of Imatinib in 2001, Dasatinib and Nilotinib have been approved for use in Imatinib resistant or intolerant as well as front line treatment for CML cases. The most common side effects of these kinase inhibitors include myelosuppression, nausea, vomiting, diarrhea, mild skin rash, and Q Tc prolongation, but serious allergic reactions are rare. Here, we present a case series of Nilotinib induced dermatologic toxicities.

Key words: Nilotinib; Skin Rash; Chronic Myeloid Leukemia



Share this Article


Advertisement
Journal of Interdisciplinary Histopathology

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons